As we have said from day one, Virta will always be committed to an evidence-based approach to reversing type 2 diabetes. Our company launch highlighted this philosophy and showcased the promising results from our clinical trial. At 10 weeks, 91% of our 262 patients with type 2 diabetes remained active in the trial and experienced an average HbA1c reduction from 7.6 to 6.5% and weight loss of 7.2%. Most notably, these results were accomplished while reducing or eliminating medications in most patients.
Our goal, though, is to reverse diabetes in millions of people safely and sustainably—where success is not measured in weeks but in years. To that end, our trial is designed to follow hundreds of patients for two years. Our research team and collaborators are now gathering data on patient outcomes at one year and we look forward to publishing those results in the peer-reviewed scientific literature.
In the meantime, we are excited to share a snapshot of the type 2 diabetes patients in the trial at six months. Trial retention remains excellent at 89% and weight loss has continued—patients lost 12% of their body weight on average.
Our patients also had the option to check their HbA1c at 6 months and over 100 did so, with their average HbA1c declining further to 6.1%. While this is only a partial data set, it is naturally creating excitement for the full laboratory results with all patients checking in.
Our team at Virta is both honored and excited to be working with each of our patients on an individualized basis to reverse their diabetes and restore their metabolic health in ways that are sustainable for them. A recent report suggests the societal impact of diabetes is even greater than previously realized accounting for 12% of U.S. deaths (rather than 3.3%) and making diabetes the third leading cause of death in the country (rather than seventh) after heart disease and cancer. This is all the more reason why we at Virta are taking on this tremendous challenge and working so hard to reverse diabetes in millions of people.